Shin James, Truong Quynh A
Department of Radiology, Weill Cornell Medicine, New York City, USA.
Curr Treat Options Cardiovasc Med. 2018 Oct 25;20(12):95. doi: 10.1007/s11936-018-0692-1.
Describe and evaluate the integration of 3D printing-related innovations into current cardiovascular treatment paradigms and examine the state of regulatory and reimbursement hurdles ahead.
Mounting years of clinical experience have established the utility of printed models of patient anatomy in numerous treatment and teaching scenarios, most notably as pre- and intra-procedural planning tools guiding decision-making for congenital heart disease and catheter-based interventions. In part due to a continued lack of reimbursement and under-defined (and slow to evolve) regulatory status, these use cases remain largely investigational even as they grow increasingly routine. Patients, physicians, and/or imaging centers therefore remain burdened by the associated cost to create such models, and the perceptual and decision-making enhancements, while demonstrable and significant, still may not clearly or independently justify a potentially high cost. Simulation and implantable device applications may represent a deeper well of unrealized value in cardiovascular intervention; however, further development of these applications relies on-and is throttled by-progress in material science and tissue-engineering research. The relevance of simulation applications in recent years is also now in competition with digital analogs including augmented and virtual reality. Innovative incorporation of alternative manufacturing processes such as porous scaffold infusion, injection molding, and vascular mesh forming can provide immediate access to more realistic tissue-mimicking materials and custom implantable devices, while comparable and directly printable materials continue to be developed. Tissue-engineering applications remain years if not decades away from a more substantive role in translatable clinical research. Regulatory challenges associated with in-house manufacture of implantable investigational devices are complex and subject to change, and the success of some in navigating these hurdles in non-cardiovascular applications is instructive and encouraging. Complex geometries characterizing cardiovascular anatomy are an ideal use case for translating the perceptual advantages of printed models of patient anatomy into better decision-making, especially so in the setting of congenital or post-surgical anatomy. Procedural planning applications take further advantage of the demonstrably robust dimensional reproduction of patient anatomy, with notably rapid integration into surgical and catheter-based intervention workflows. Despite a continued lack of codification in the healthcare system, 2018 could be a milestone year for 3D printing services, pending a successful application for a CPT Category III designation.
描述并评估3D打印相关创新在当前心血管治疗模式中的整合情况,并审视未来监管和报销方面的障碍现状。
多年来不断积累的临床经验已证实患者解剖结构打印模型在众多治疗和教学场景中的实用性,最显著的是作为先天性心脏病和基于导管的介入治疗术前和术中规划工具,用于指导决策。部分由于持续缺乏报销支持以及监管状态定义不明确(且发展缓慢),这些用例尽管日益常规化,但在很大程度上仍处于研究阶段。因此,患者、医生和/或影像中心仍需承担创建此类模型的相关成本,而感知和决策方面的提升虽然显著且可证明,但可能仍无法明确或独立地证明潜在的高成本是合理的。模拟和可植入设备应用在心血管介入中可能代表着更深层次的未实现价值;然而,这些应用的进一步发展依赖于材料科学和组织工程研究的进展,同时也受到其制约。近年来模拟应用的相关性现在也与包括增强现实和虚拟现实在内的数字模拟技术形成竞争。创新性地纳入替代制造工艺,如多孔支架灌注、注塑成型和血管网成型,可以立即获得更逼真的组织模拟材料和定制可植入设备,同时仍在不断开发可比且可直接打印的材料。组织工程应用距离在可转化临床研究中发挥更实质性作用即便不是几十年,也还有数年时间。与内部制造可植入研究设备相关的监管挑战复杂且可能发生变化,一些在非心血管应用中跨越这些障碍的成功案例具有指导意义且令人鼓舞。心血管解剖结构的复杂几何形状是将患者解剖结构打印模型的感知优势转化为更好决策的理想用例,在先天性或术后解剖结构的情况下尤其如此。程序规划应用进一步利用了患者解剖结构维度再现的强大功能,能显著快速地整合到手术和基于导管的介入工作流程中。尽管医疗保健系统中仍缺乏编码,但如果3D打印服务成功申请到CPT III类指定,2018年可能成为其里程碑式的一年。